Tyrosine kinase inhibitorFDA-approvedSecond-line
Lorlatinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, around 75% of patients with ALK-positive non-small cell lung cancer achieved an objective response, with median progression-free survival of approximately 18 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Lorlatinib as a First-line Treatment for ALK-positive Lung Cancer in Chinese Adults | Lung Cancer | preclinical | — | Source → |
| Testing Lorlatinib with Local Consolidation Therapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Lorlatinib Cost-Effective for Lung Cancer Patients in Italy | Lung Cancer | phase-3 | Lorlatinib provided higher benefits (+2.01 life-years; +1.66 quality-adjusted life-years) at lower costs (-€19,210 per patient) compared to alectinib. | Source → |
| Rare Side Effects Found in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Lorlatinib Linked to Rare but Specific Neuropsychiatric Side Effects | Lung Cancer | observational | — | Source → |
| Lorlatinib Shows Promise in Lung Cancer Patients Who Have Tried Other Treatments | Lung Cancer | preclinical | The objective response rate was 42% (95% CI, 31%-55%). | Source → |
| Lorlatinib Efficacy and Safety in Lung Cancer Patients | Lung Cancer | observational | The objective response rate was 82.9% in the first-line treatment cohort, and the disease control rate was 100%. The median progression-free survival had not yet been reached in the first-line treatment cohort, and the median progression-free survival was 16.8 months in the subsequent-line treatment cohort. | Source → |
| Lorlatinib Shows Promise in Lung Cancer Patients Who Failed Earlier Treatments | Lung Cancer | observational | The overall objective response rate was 64.6%, with the disease control rate of 96.3%. | Source → |
| New Lung Cancer Treatments Show Promise but Raise Concerns | Lung Cancer | phase-3 | — | Source → |
| Lorlatinib Linked to Higher Heart Risks in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Weight Gain Risk for Lung Cancer Patients on Lorlatinib | Lung Cancer | observational | Patients receiving lorlatinib experienced significantly higher maximum weight gain (mean 13.5% [95% confidence interval 10.8-16.2]) | Source → |
| Lorlatinib Monotherapy Shows Promise for Rare Lung Cancer | Lung Cancer | observational | — | Source → |
| Lorlatinib Therapy Linked to Unusual Lipid Levels | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.